pragma.vision Technology observatory & strategic foresight

Verification register Bio, Health & Neuro

Readiness verdict

ANKTIVA (nogapendekin alfa inbakicept)

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-08-20
Revision
1
Method
v1.3.0

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Ready

Primary summary from verified readiness

Confidence
78% · stale
Computed at
2026-08-20T10:51:29.058288+00:00
Claimed
90

Public ambition and stated capability

Reported
77

Observed practitioner reporting

Verified
59

Independently supported evidence

Gap
+31

Claimed leads verified

Evidence strength Strong

Decision

What the current evidence supports

Human editorial judgment · 2026-08-20

Adopt with guardrails

Why
FDA-approved and now EU-authorized with a strong 71% CR and high bladder-preservation rates, but conditional authorization plus single-arm pivotal design are the guardrails.
Next
Monitor confirmatory/long-term data underpinning the EU conditional authorization and real-world durability beyond the single-arm cohort

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
7
Tier 1
5
Tier 2
0
Tier 3
2
Supports
4
Contradicts
2
Context
1
Latest observed
2026-02-18

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

  1. 2026-07-19 Reading moved from ready to ready.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.